InsiderTrades.com logo

DMRA Insider Trading

Insider Ownership Percentage: 10.46%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $20,838.98

Damora Therapeutics, Inc. Common Stock Insider Trading History Chart

This chart shows the insider buying and selling history at Damora Therapeutics, Inc. Common Stock by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Damora Therapeutics, Inc. Common Stock Share Price & Price History

Current Price: $25.82
Price Change: ▼ Price Decrease of -0.87 (-3.26%)
As of 04/10/2026 05:00 PM ET

This chart shows the closing price history over time for DMRA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Damora Therapeutics, Inc. Common Stock Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2026Hans T. SchambyeCEOSell700$21.38$14,966.004,682View SEC Filing Icon  
1/2/2026Lori FirmaniCFOSell135$21.41$2,890.35931View SEC Filing Icon  
7/3/2025Hans T. SchambyeCEOSell735$3.38$2,484.304,022View SEC Filing Icon  
7/3/2025Lori FirmaniCFOSell147$3.39$498.33692View SEC Filing Icon  
1/3/2025Hans T. SchambyeCEOSell1,341$5.60$7,509.603,397View SEC Filing Icon  
1/3/2025Lori FirmaniCFOSell261$5.63$1,469.43465View SEC Filing Icon  
7/31/2023Orbimed Advisors LlcMajor ShareholderSell8,376$75.00$628,200.005,421View SEC Filing Icon  
7/25/2023Orbimed Advisors LlcMajor ShareholderSell1,568$73.00$114,464.006,486View SEC Filing Icon  
7/13/2023Orbimed Advisors LlcMajor ShareholderSell7,788$60.00$467,280.006,798View SEC Filing Icon  
4/17/2023Orbimed Advisors LlcMajor ShareholderSell523$49.25$25,757.757,190View SEC Filing Icon  
4/14/2023Orbimed Advisors LlcMajor ShareholderSell1,657$46.50$77,050.507,216View SEC Filing Icon  
4/12/2023Orbimed Advisors LlcMajor ShareholderSell94$45.25$4,253.507,328View SEC Filing Icon  
4/10/2023Orbimed Advisors LlcMajor ShareholderSell2,049$44.75$91,692.757,436View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

14.20% of Damora Therapeutics, Inc. Common Stock stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DMRA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Damora Therapeutics, Inc. Common Stock Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/18/2026Ikarian Capital LLC285,710$6.57M0.5%N/A17.857%Search for SEC Filing on Google Icon
2/18/2026Janus Henderson Group PLC1,739$40K0.0%N/A0.109%Search for SEC Filing on Google Icon
2/18/2026Boothbay Fund Management LLC95,798$2.20M0.0%N/A5.987%Search for SEC Filing on Google Icon
2/17/2026Jain Global LLC120,566$2.77M0.0%N/A7.535%Search for SEC Filing on Google Icon
2/12/2026Remedium Capital Partners LLC120,473$2.77M1.6%N/A7.544%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC11,573$0.27M0.0%N/A0.725%Search for SEC Filing on Google Icon
1/30/2026Sigma Planning Corp14,500$0.33M0.0%N/A0.906%Search for SEC Filing on Google Icon
11/17/2025Connective Capital Management LLC26,956$100K0.1%N/A2.027%Search for SEC Filing on Google Icon
11/17/2025Novo Holdings A S86,579$0.32M0.0%-13.3%6.510%Search for SEC Filing on Google Icon
11/14/2025Virtu Financial LLC13,128$49K0.0%N/A0.987%Search for SEC Filing on Google Icon
11/14/2025Two Sigma Investments LP20,296$76K0.0%N/A1.526%Search for SEC Filing on Google Icon
2/17/2025Squarepoint Ops LLC12,701$59K0.0%N/A0.962%Search for SEC Filing on Google Icon
2/13/2025Renaissance Technologies LLC15,044$70K0.0%-29.6%1.140%Search for SEC Filing on Google Icon
10/24/2024Novo Holdings A S99,913$1.21M0.1%-96.0%0.369%Search for SEC Filing on Google Icon
11/15/2023Laurion Capital Management LP88,580$64K0.0%-53.5%0.327%Search for SEC Filing on Google Icon
8/8/2023Belvedere Trading LLC15,037$38K0.0%N/A0.055%Search for SEC Filing on Google Icon
8/4/2023Simplex Trading LLC11,399$28K0.0%+3,699.7%0.042%Search for SEC Filing on Google Icon
8/2/2023MAI Capital Management245,281$0.62M0.0%-4.0%0.956%Search for SEC Filing on Google Icon
7/10/2023Trust Co. of Toledo NA OH22,432$57K0.0%+86.9%0.087%Search for SEC Filing on Google Icon
5/10/2023MAI Capital Management255,453$0.51M0.0%+9.5%0.995%Search for SEC Filing on Google Icon
2/9/2023MAI Capital Management233,283$0.27M0.0%-31.2%0.912%Search for SEC Filing on Google Icon
9/16/2022Federated Hermes Inc.40,000$69K0.0%+53.8%0.158%Search for SEC Filing on Google Icon
7/19/2022MAI Capital Management320,860$0.56M0.0%N/A1.270%Search for SEC Filing on Google Icon
7/15/2022Marquette Asset Management LLC60,244$0.10M0.0%+31.6%0.238%Search for SEC Filing on Google Icon
4/26/2022Marquette Asset Management LLC45,765$0.10M0.0%+25.4%0.181%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Damora Therapeutics, Inc. Common Stock logo
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Read More on Damora Therapeutics, Inc. Common Stock

Today's Range

Now: $25.82
Low: $25.55
High: $27.88

50 Day Range

MA: $26.81
Low: $18.14
High: $32.30

52 Week Range

Now: $25.82
Low: $2.14
High: $38.33

Volume

287,217 shs

Average Volume

276,563 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Who are the company insiders with the largest holdings of Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock's top insider shareholders include:
  1. Orbimed Advisors Llc (Major Shareholder)
  2. Hans T Schambye (CEO)
  3. Lori Firmani (CFO)
  4. Bertil Lindmark (Insider)
  5. Jonathan Freve (CFO)
  6. Garrett Winslow (General Counsel)
Learn More about top insider investors at Damora Therapeutics, Inc. Common Stock.

Damora Therapeutics, Inc. Common Stock Active Insiders

Hans T Schambye
Hans T Schambye (Age 60)
CEO
1 recent trades
Jonathan Freve
Jonathan Freve (Age 48)
CFO
Garrett Winslow
Garrett Winslow (Age 47)
General Counsel
Bertil Lindmark
Bertil Lindmark (Age 71)
Insider